Related Experiment Video

Updated: Jul 5, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs

Sara Janowska1, Serhii Holota2, Roman Lesyk2

  • 1Department of Pathobiochemistry and Interdisciplinary Applications of Ion Chromatography, Biomedical Sciences, Medical University of Lublin, 1 Chodzki Street, 20-093 Lublin, Poland.

Molecules (Basel, Switzerland)
|January 23, 2024
PubMed

Insights

This review explores new aromatase inhibitors for breast cancer treatment. It examines how structural changes impact the anticancer activity of steroidal and non-steroidal compounds.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Oncology

Background:

  • Aromatase enzyme is key in estrogen biosynthesis, fueling hormone-receptor-positive breast cancers.
  • Estrogen's role in cancer growth makes aromatase a critical therapeutic target.
  • Aromatase inhibitors are vital in breast cancer treatment strategies.

Purpose of the Study:

  • To review recent advancements in novel aromatase inhibitor development.
  • To analyze structure-activity relationships for enhanced anticancer efficacy.
  • To identify promising research directions for new aromatase-targeting drugs.

Main Methods:

  • Comprehensive literature review of studies published in the last decade.
  • Analysis of steroidal and non-steroidal aromatase inhibitors.
  • Evaluation of structure modification impacts on anticancer activity.

Main Results:

  • Identified key structural modifications enhancing aromatase inhibitory potential.
  • Highlighted promising new chemical scaffolds for inhibitor design.
  • Correlated specific structural features with improved anticancer effects.

Conclusions:

  • Continued research into aromatase inhibitors offers significant therapeutic potential for breast cancer.
  • Structure-based drug design is crucial for developing more effective anticancer agents.
  • Targeting aromatase remains a highly promising strategy in oncology.
Keywords:
anticancer activityaromatase inhibitorssteroidal and non-steroidal compounds

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.6K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K